NCT06663059View on ClinicalTrials.gov

Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

September 1, 2027

Conditions
Esophageal Cancer
Interventions
DRUG

Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle

"Each treatment cycle is 3 weeks long (Q3W), with a total of 2 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion."

DRUG

Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle

"Each treatment cycle is 3 weeks long (Q3W), with a total of 4 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion."

Trial Locations (1)

710038

RECRUITING

Tangdu Hospital Affiliated to the Fourth Military Medical University, Xi'an

All Listed Sponsors
lead

Tang-Du Hospital

OTHER